
January 22, 2024
RegMed Investors (RMi) Closing Bell: got some
January 22, 2024
RegMed Investors’ (RMi) pre-open: Looking for some more sector equity highs
January 20, 2024
RegMed Investors (RMi) Closing Bell: glad the week is over; we need to review the oversold
January 19, 2024
RegMed Investors’ (RMi) pre-open: will it or a would it
January 18, 2024
RegMed Investors (RMi) Research Note: Mesoblast (MESO) FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L)
January 18, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector loses muscle strength while clinging to newest bottoms
January 18, 2024
RegMed Investors’ (RMi) pre-open: the hits just kept on coming
January 17, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector clings to newest bottoms
January 17, 2024
RegMed Investors’ (RMi) pre-open: still looking-up from the abyss
January 16, 2024
RegMed Investors (RMi) Closing Bell: rock-in the limbo dance
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors